GlaxoSmithKline PLC Earnings Estimate

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

Many public companies, such as GlaxoSmithKline PLC, manage the perception of their earnings on regular bases to make sure that analyst estimates are accurate. Future earnings calculations are essential input when attempting to value a firm. GlaxoSmithKline PLC is projected to generate 2.9 in earnings per share on 31st of December 2020. GlaxoSmithKline PLC earnings estimates module stress-tests analyst consensus about projected GlaxoSmithKline PLC EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Please check Risk vs Return Analysis.

Search Earnings Estimates

 
Refresh
The current Gross Profit is estimated to increase to about 22.5 B. The current Profit Margin is estimated to increase to 0.14
Earnings
Estimates (6)
LowProjected EPSHigh
2.832.902.98
Details
Hype
Prediction
LowEstimated ValueHigh
38.3739.9041.43
Details
Intrinsic
Valuation
LowReal ValueHigh
39.5741.1042.63
Details
11 Analysts
Consensus
LowTarget PriceHigh
42.1050.2758.00
Details

GlaxoSmithKline PLC Earnings Boundaries

Current EPS
0.99
12th of July 2020
2.83
Lowest
Estimated EPS
2.9
2.98
Highest
GlaxoSmithKline PLC Earnings per Share projection breakdown
Calculation of earning per share of GlaxoSmithKline PLC is based on official Zacks consensus of 3 analysts regarding GlaxoSmithKline PLC future annual earnings. Given the historical accuracy of 92.89%, the future earnings per share of GlaxoSmithKline PLC is estimated to be 2.9 with lowest and highest values of 2.83 and 2.98 respectively. Please note that this consensus of annual earnings estimates for GlaxoSmithKline PLC is an estimate of EPS before non-recurring items and including employee stock options expenses
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2020

3

92.89%

0.99

2.9

GlaxoSmithKline PLC Earnings per Share Projection vs Actual

GlaxoSmithKline PLC Estimated Earnings per Share

About GlaxoSmithKline PLC Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of GlaxoSmithKline PLC earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current GlaxoSmithKline PLC estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as GlaxoSmithKline PLC fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.' Please read more on our stock advisor page.
Last ReportedProjected for 2020
Accumulated Retained Earnings Deficit4.5 B4.9 B
Earning Before Interest and Taxes EBIT6.5 BB
Earnings per Basic Share 1.88  1.67 
Earnings per Diluted Share 1.85  1.65 
Price to Earnings Ratio 19.02  25.29 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA6.5 BB
Earnings before Tax5.6 B5.2 B
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on BATS Exchange. It employs 99437 people.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page